Absorption, Distribution, Metabolism, Excretion, and Toxicity Evaluation in Drug Discovery. 14. Prediction of Human Pregnane X Receptor Activators by Using Naive Bayesian Classification Technique.

The activation of pregnane X receptor (PXR), a member of the nuclear receptor (NR) superfamily, can mediate potential drug-drug interactions, and therefore, prediction of PXR activation is of great importance for evaluating drug metabolism and toxicity. In this study, based on 532 structurally diverse compounds, we present a comprehensive analysis with the aim to build accurate classification models for distinguishing PXR activators from nonactivators by using a naive Bayesian classification technique. First, the distributions of eight important molecular physicochemical properties of PXR activators versus nonactivators were compared, illustrating that the hydrophobicity-related molecular descriptors (AlogP and log D) show slightly better capability to discriminate PXR activators from nonactivators than the others. Then, based on molecular physicochemical properties, VolSurf descriptors, and molecular fingerprints, naive Bayesian classifiers were developed to separate PXR activators from nonactivators. The results demonstrate that the introduction of molecular fingerprints is quite essential to enhance the prediction accuracy of the classifiers. The best Bayesian classifier based on the 21 physicochemical properties, VolSurf descriptors, and LCFC_10 fingerprints descriptors yields a prediction accuracy of 92.7% for the training set based on leave-one-out (LOO) cross-validation and of 85.2% for the test set. Moreover, by exploring the important structural fragments derived from the best Bayesian classifier, we observed that flexibility is an important structural pattern for PXR activation. In addition, chemical compounds containing more halogen atoms, unsaturated alkanes chains relevant to π-π stacking, and fewer nitrogen atoms tend to be PXR activators. We believe that the naive Bayesian classifier can be used as a reliable virtual screening tool to predict PXR activation in the drug design and discovery pipeline.

[1]  S. Kliewer,et al.  Use of the nuclear receptor PXR to predict drug interactions. , 2000, Toxicology.

[2]  L. Moore,et al.  St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Ghose,et al.  Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods , 1998 .

[4]  Timothy M Willson,et al.  The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. , 2002, Endocrine reviews.

[5]  L. Stanley,et al.  PXR and CAR: Nuclear Receptors which Play a Pivotal Role in Drug Disposition and Chemical Toxicity , 2006, Drug metabolism reviews.

[6]  Igor V. Tetko,et al.  Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices , 2001, J. Chem. Inf. Comput. Sci..

[7]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[8]  D. Rogers,et al.  Using Extended-Connectivity Fingerprints with Laplacian-Modified Bayesian Analysis in High-Throughput Screening Follow-Up , 2005, Journal of biomolecular screening.

[9]  Junmei Wang,et al.  Structure – ADME relationship: still a long way to go? , 2008, Expert opinion on drug metabolism & toxicology.

[10]  A. D. Rodrigues,et al.  Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. , 2006, Current drug metabolism.

[11]  B G Lake,et al.  Quantitative structure--activity relationships for inducers of cytochromes P450 and nuclear receptor ligands involved in P450 regulation within the CYP1, CYP2, CYP3 and CYP4 families. , 2002, Toxicology.

[12]  J. Sahi,et al.  Current Industrial Practices in Assessing CYP450 Enzyme Induction: Preclinical and Clinical , 2008, The AAPS Journal.

[13]  Y. Z. Chen,et al.  In Silico Prediction of Pregnane X Receptor Activators by Machine Learning Approache , 2007, Molecular Pharmacology.

[14]  R. Lester,et al.  Formation of three types of glucuronides of 6-hydroxy bile acids by rat liver microsomes. , 1988, Journal of lipid research.

[15]  Max K. Leong,et al.  Predicting activation of the promiscuous human pregnane X receptor by pharmacophore ensemble/support vector machine approach. , 2011, Chemical research in toxicology.

[16]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 6. Can Oral Bioavailability in Humans Be Effectively Predicted by Simple Molecular Property-Based Rules? , 2007, J. Chem. Inf. Model..

[17]  R. Evers,et al.  Attenuating pregnane X receptor (PXR) activation: A molecular modelling approach , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  Ann Richard,et al.  Evaluation of high-throughput genotoxicity assays used in profiling the US EPA ToxCast chemicals. , 2009, Regulatory toxicology and pharmacology : RTP.

[19]  S. Ekins.  Predicting undesirable drug interactions with promiscuous proteins in silico. , 2004, Drug discovery today.

[20]  F. Sun,et al.  Molecular insights into the promiscuous interaction of human pregnane X receptor (hPXR) with diverse environmental chemicals and drug compounds. , 2014, Chemosphere.

[21]  Virginie Nahoum,et al.  Discovery of a Highly Active Ligand of Human Pregnane X Receptor: A Case Study from Pharmacophore Modeling and Virtual Screening to “In Vivo” Biological Activity , 2007, Molecular Pharmacology.

[22]  Thierry Langer,et al.  The Identification of Ligand Features Essential for PXR Activation by Pharmacophore Modeling , 2005, J. Chem. Inf. Model..

[23]  Sean Ekins,et al.  Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites , 2007, Molecular Pharmacology.

[24]  T. Halgren.  MMFF VI. MMFF94s option for energy minimization studies , 1999, J. Comput. Chem..

[25]  W. Xie,et al.  Orphan nuclear receptor-mediated xenobiotic regulation in drug metabolism. , 2004, Drug discovery today.

[26]  Sichao Wang,et al.  Recent developments in computational prediction of HERG blockage. , 2013, Current topics in medicinal chemistry.

[27]  P. Carrupt,et al.  Molecular fields in quantitative structure–permeation relationships: the VolSurf approach , 2000 .

[28]  Sean Ekins,et al.  Prediction of human drug metabolizing enzyme induction. , 2003, Current drug metabolism.

[29]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 7. Prediction of Oral Absorption by Correlation and Classification , 2007, J. Chem. Inf. Model..

[30]  Sean Ekins,et al.  Application of data mining approaches to drug delivery. , 2006, Advanced drug delivery reviews.

[31]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[32]  Tingjun Hou,et al.  Drug-likeness analysis of traditional Chinese medicines: prediction of drug-likeness using machine learning approaches. , 2012, Molecular pharmaceutics.

[33]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.

[34]  L. Moore,et al.  The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution , 2000 .

[35]  Sean Ekins,et al.  Identification and Validation of Novel Human Pregnane X Receptor Activators among Prescribed Drugs via Ligand-Based Virtual Screening , 2011, Drug Metabolism and Disposition.

[36]  William J. Welsh,et al.  Hybrid Scoring and Classification Approaches to Predict Human Pregnane X Receptor Activators , 2009, Pharmaceutical Research.

[37]  Wissem Mnif,et al.  Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[38]  Lei Chen,et al.  ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques. , 2011, Molecular pharmaceutics.

[39]  Qian Zhang,et al.  Modeling Compound-Target Interaction Network of Traditional Chinese Medicines for Type II Diabetes Mellitus: Insight for Polypharmacology and Drug Design , 2013, J. Chem. Inf. Model..

[40]  P. Ascenzi,et al.  Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. , 2009, Molecular aspects of medicine.

[41]  H. Matter,et al.  Development of in silico filters to predict activation of the pregnane X receptor (PXR) by structurally diverse drug-like molecules. , 2012, Bioorganic & medicinal chemistry.

[42]  Youyong Li,et al.  ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage. , 2012, Molecular pharmaceutics.

[43]  Sean Ekins,et al.  Machine learning methods and docking for predicting human pregnane X receptor activation. , 2008, Chemical research in toxicology.

[44]  Sean Ekins,et al.  Computational Discovery of Novel Low Micromolar Human Pregnane X Receptor Antagonists , 2008, Molecular Pharmacology.

[45]  R. Evans,et al.  An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Wei Zhang,et al.  Recent advances in computational prediction of drug absorption and permeability in drug discovery. , 2006, Current medicinal chemistry.

[47]  Sean Ekins,et al.  A pharmacophore for human pregnane X receptor ligands. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[48]  William J. Welsh,et al.  QSAR models in receptor-mediated effects: the nuclear receptor superfamily , 2003 .

[49]  Tingjun Hou,et al.  Development and Evaluation of an Integrated Virtual Screening Strategy by Combining Molecular Docking and Pharmacophore Searching Based on Multiple Protein Structures , 2013, J. Chem. Inf. Model..

[50]  E. B. Wedebye,et al.  QSAR model for human pregnane X receptor (PXR) binding: screening of environmental chemicals and correlations with genotoxicity, endocrine disruption and teratogenicity. , 2012, Toxicology and applied pharmacology.

[51]  R. Saracci,et al.  Describing the validity of carcinogen screening tests. , 1979, British Journal of Cancer.

[52]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..